Evidence map›Paper›PMID 31166404›Full record

ArticleAnais brasileiros de dermatologia2019

Consensus on the diagnostic and therapeutic management of chronic spontaneous urticaria in adults - Brazilian Society of Dermatology.

Paulo Ricardo Criado, Celina Wakisaka Maruta, Alice de Oliveira de Avelar Alchorne, Andréa Machado Coelho Ramos, Bernardo Gontijo, Josemir Belo Dos Santos, Luis Eduardo Agner Machado Martins, Maria Cecília Rivitti-Machado, Maria Regina Cavariani Silvares, Mario Cezar Pires and 6 more

Open access · goldAbstract readConsensus Statement
In one paragraph

Article in Anais brasileiros de dermatologia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 10 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 10 institutions in 1 country.

Paulo Ricardo CriadoFaculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.
Celina Wakisaka MarutaDepartment of Dermatology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.
Alice de Oliveira de Avelar AlchorneUniversidade Federal de Pernambuco, Recife, PE, Brazil.
Andréa Machado Coelho RamosDermatology Service, Hospital das Clinicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
Bernardo GontijoFaculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
Josemir Belo Dos SantosCentro de Ciências Médicas, Faculdade de Medicina, Universidade Federal de Pernambuco, Recife, PE, Brazil.
Luis Eduardo Agner Machado MartinsDermatology Service, Faculdade Evangélica de Curitiba, Curitiba, PR, Brazil.
Maria Cecília Rivitti-MachadoHospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.
Maria Regina Cavariani SilvaresDepartment of Dermatology and Radiotherapy, Universidade Estadual Paulista, Botucatu, SP, Brasil.
Mario Cezar PiresHospital Padre Bento de Guarulhos, São Paulo, SP, Brazil.
Patricia Karla de SouzaUrticaria Outpatient Clinic, Department of Dermatology, Universidade Federal de São Paulo, São Paulo, SP, Brazil.
Raquel Leão OrfaliHospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.
Renan Rangel BonamigoHospital de Clínicas de Porto Alegre, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
Roberta Buense BedrikowDermatology Clinic, Santa Casa de Misericórdia de São Paulo, São Paulo, SP, Brazil.
Roberta Fachini Jardim CriadoFaculdade de Medicina do ABC, São Paulo, SP, Brazil.
Zilda Najjar Prado de OliveiraHospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.
Universidade de São Paulo · BRUniversidade Federal de Minas Gerais · BRUniversidade Federal de Pernambuco · BRFaculdade de Medicina do ABC · BRHospital do Servidor Público Estadual · BRHospital Universitário Evangélico de Curitiba · BRIrmandade da Santa Casa de Misericórdia de São Paulo · BRUniversidade Estadual Paulista (Unesp) · BRUniversidade Federal de São Paulo · BRUniversidade Federal do Rio Grande do Sul · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUrticarias are frequent diseases, with 15% to 20% of the population presenting at least one acute episode in their lifetime. Urticaria are classified in acute ( ≤ 6 weeks) or chronic (> 6 weeks). They may be induced or spontaneous.

objectivesTo verify the diagnostic and therapeutic recommendations in chronic spontaneous urticaria (CSU), according to the experience of Brazilian experts, regarding the available guidelines (international and US).

methodsA questionnaire was sent to Brazilian experts, with questions concerning diagnostic and therapeutic recommendations for CSU in adults.

resultsSixteen Brazilian experts answered the questionnaire related to diagnosis and therapy of CSU in adults and data were analyzed. Final text was written, considering the available guidelines (International and US), adapted to the medical practices in Brazil. Diagnostic work up in CSU is rarely necessary. Biopsy of skin lesion and histopathology may be indicated to rule out other diseases, such as, urticarial vasculitis. Other laboratory tests, such as complete blood count, CRP, ESR and thyroid screening. Treatment of CSU includes second-generation anti-histamines (sgAH) at licensed doses, sgAH two, three to fourfold doses (non-licensed) and omalizumab. Other drugs, such as, cyclosporine, immunomodulatory drugs and immunosuppressants may be indicated (non-licensed and with limited scientific evidence).

conclusionsMost of the Brazilian experts in this study partially agreed with the diagnostic and therapeutic recommendations of the International and US guidelines. They agreed with the use of sgAH at licensed doses. Increase in the dose to fourfold of sgAH may be suggested with restrictions, due to its non-licensed dose. Sedating anti-histamines, as suggested by the US guideline, are indicated by some of the Brazilian experts, due to its availability. Adaptations are mandatory in the treatment of CSU, due to scarce or lack of other therapeutic resources in the public health system in Brazil, such as omalizumab or cyclosporine.

Indexed as

AdultAnti-Allergic AgentsBrazilChronic DiseaseCyclosporinsDermatologyHistamine H1 Antagonists, Non-SedatingHumansImmunosuppressive AgentsOmalizumabSeverity of Illness IndexSocieties, MedicalUrticariaAnti-Allergic AgentsCyclosporinsHistamine H1 Antagonists, Non-SedatingImmunosuppressive AgentsOmalizumab

Identifiers

PMID31166404
PMCPMC6544033
OpenAlexW2946835795

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.